GONADOTROPIN-RELEASING HORMONE (GNRH) RECEPTOR ANTAGONIST
Orilissa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe pain caused by endometriosis. Orilissa may be referred to by its drug name, elagolix.
Orilissa is a gonadotropin-releasing hormone (GnRH) receptor antagonist. Orilissa is believed to work by reducing estrogen levels.
How do I take it?
Prescribing information states that Orilissa is taken orally either once or twice daily, depending on dosage.
Orilissa is available in tablet form.
The FDA-approved label for Orilissa lists common side effects including headaches, insomnia, depression, anxiety, nausea, joint pain, amenorrhea (absence of menstrual periods), and menopausal symptoms such as hot flashes, night sweats, and mood changes.
Rare but serious side effects listed for Orilissa include loss of bone mineral density, suicidal thoughts or behavior, reduced ability to recognize pregnancy, harm to the fetus (in pregnant women), and elevated levels of liver enzymes, which can be associated with liver damage. Hormonal contraception may be less effective while taking Orilissa and for a week after discontinuing the medication. It may be more difficult to recognize signs of pregnancy while taking Orilissa.
For more details about this treatment, visit:
Orilissa.com — AbbVie